BioSpace News Archive

Pliant Therapeutics, Inc. today announced that it presented Phase 2a clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2023 International Conference, held from May 19 through May 24, 2023.

Eloxx Pharmaceuticals, Inc. today announced that the company intends to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations, following the achievement of remission in one patient in its Phase 2 clinical study.

BIOREM Inc. today announced results for the three month period ended March 31, 2023.

Lassen Therapeutics presented new preclinical and Phase I data of LASN01 for treatment of pulmonary fibrosis, at today’s American Thoracic Society (ATS) Annual Meeting being held in Washington DC.

With the launch of a new website dedicated to their global clinical trials, Paradigm Biopharmaceuticals Ltd. aims to provide relief to millions of osteoarthritis sufferers worldwide by developing a new injectable drug.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Burkhard Blank, MD, has joined the company as Executive Vice President, Research & Development and Chief Medical Officer.

Eterna Therapeutics Inc. today announced the appointment of Megan Yung as Chief Strategy Officer and General Counsel.

Pyxis Oncology, Inc. and Apexigen, Inc. announced a definitive agreement by which Pyxis Oncology will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share.

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company, with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for three months ended March 31, 2023.

Syndax Pharmaceuticals, Inc. today announced that members of its management team will participate in two upcoming investor conferences.